Prab: CSV import

2024-03-08T13:21:50Z

CSV import

New page

'''Avacincaptad pegol''' is an investigational drug that is being studied for the treatment of [[Age-related macular degeneration|age-related macular degeneration (AMD)]]. It is a [[PEGylated]] aptamer that binds to and inhibits the activity of [[complement factor 5|complement factor 5 (C5)]], a protein that plays a key role in the [[complement system]], part of the body's immune response.

==Mechanism of action==
Avacincaptad pegol works by binding to C5, preventing it from being cleaved into its active forms, C5a and C5b. This inhibits the formation of the [[membrane attack complex]], which can cause damage to the [[retina]] in AMD.

==Clinical trials==
Several [[clinical trial]]s have been conducted to evaluate the safety and efficacy of avacincaptad pegol in patients with AMD. These trials have shown promising results, with patients receiving the drug showing a slower progression of the disease compared to those receiving a [[placebo]].

==Potential side effects==
As with any drug, avacincaptad pegol may cause side effects. In clinical trials, the most common side effects reported were injection site reactions, eye pain, and [[conjunctivitis]]. However, these side effects were generally mild and resolved on their own.

==Future directions==
Further research is needed to fully understand the potential benefits and risks of avacincaptad pegol. If proven safe and effective, it could provide a new treatment option for patients with AMD, a disease for which there is currently no cure.

==See also==
* [[Age-related macular degeneration]]
* [[Complement system]]
* [[Clinical trial]]

[[Category:Drugs]]
[[Category:Investigational drugs]]
[[Category:Ophthalmology]]
[[Category:Pharmacology]]

{{pharmacology-stub}}

Avacincaptad pegol - Revision history

Prab: CSV import